Alprostadil (Caverject/MUSE) and Trazodone Interaction

Why This Interaction Matters

Alprostadil and trazodone each carry independent FDA-label warnings for priapism, making their combination a textbook example of pharmacodynamic risk stacking. Priapism is a urologic emergency: ischemic priapism lasting beyond six hours can cause irreversible corporal fibrosis and permanent erectile dysfunction [1]. Understanding the mechanism behind this pairing helps clinicians and patients weigh the benefit of improved erectile response against a low-probability but high-consequence adverse event.

Alprostadil's Role in Erection Physiology

Alprostadil is a synthetic prostaglandin E1 (PGE1). It binds EP2 and EP4 receptors on corporal smooth-muscle cells, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP) [2]. The resulting smooth-muscle relaxation increases arterial inflow and compresses subtunical venules, producing an erection. The FDA-approved label for Caverject reports a 4% incidence of prolonged erection (>4 hours) and a 0.4% incidence of priapism requiring intervention across key trials [3].

Trazodone's Pro-Erectile Mechanism

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) prescribed primarily for major depressive disorder and off-label for insomnia. Its alpha-1 adrenergic antagonism in corporal tissue blocks the norepinephrine-mediated detumescence pathway [4]. A 1993 analysis in the Journal of Urology estimated trazodone-associated priapism at roughly 1 in 6,000 male patients, though post-marketing surveillance suggests the true rate may be higher given underreporting [5]. The FDA label for trazodone includes a boxed-section warning advising patients to seek immediate medical attention for erections persisting beyond four hours [6].

Mechanism of the Interaction

The alprostadil-trazodone interaction is pharmacodynamic, not pharmacokinetic. No significant cytochrome P450 or P-glycoprotein overlap drives this pairing. Instead, the two drugs converge on penile vascular smooth muscle through complementary pathways, each removing a separate "brake" on erection.

Dual-Pathway Smooth-Muscle Relaxation

Alprostadil raises cAMP via prostaglandin receptor activation, directly relaxing corporal smooth muscle. Trazodone blocks alpha-1 adrenergic receptors, suppressing norepinephrine-driven vasoconstriction that normally initiates detumescence [4]. The net effect: arterial inflow increases (alprostadil) while the sympathetic outflow signal to end the erection is blunted (trazodone). This two-hit mechanism reduces the physiologic safety margin against prolonged tumescence.

Why CYP Metabolism Is Not the Primary Concern

Alprostadil is rapidly metabolized by local pulmonary enzymatic oxidation during a single pass through the lungs, with a plasma half-life of 30 seconds to several minutes after intracavernosal injection [3]. Trazodone undergoes hepatic CYP3A4-mediated metabolism to its active metabolite m-chlorophenylpiperazine (mCPP) [6]. Because alprostadil clearance is almost entirely pulmonary and non-CYP-dependent, competitive enzyme inhibition between the two drugs is clinically negligible. The interaction risk is driven entirely by receptor-level pharmacodynamics in corporal tissue.

Severity Classification

Major drug-interaction databases classify this combination as moderate to serious. Lexicomp assigns a "C: Monitor therapy" rating, while Clinical Pharmacology flags the pair under its priapism-risk interaction class [7]. The American Urological Association (AUA) guidelines on erectile dysfunction note that any agent with independent priapism potential should be combined with intracavernosal therapies only under direct physician supervision [8].

Risk Stratification by Patient Profile

Not every patient faces equal risk. Men with sickle cell disease or trait, multiple myeloma, leukemia, or anatomical penile deformities (Peyronie's disease) have a baseline elevated priapism risk and should generally avoid this combination entirely [3]. Patients on concurrent anticoagulants face compounded complications because corporal aspiration for priapism management becomes more hazardous when coagulation is impaired.

Dose-Dependent Considerations

Priapism risk with alprostadil is dose-dependent. The Caverject label recommends titrating from a starting dose of 2.5 mcg, with the lowest effective dose identified in-office before home use [3]. Adding trazodone to the regimen may effectively shift the dose-response curve leftward, meaning a previously safe alprostadil dose could produce a prolonged erection when the sympathetic detumescence brake is pharmacologically weakened. No published trial has formally quantified the magnitude of this shift, which is why conservative dosing and close monitoring remain the clinical standard.

Monitoring and Clinical Management

Patients using both alprostadil and trazodone require structured monitoring that extends beyond standard follow-up for either drug alone. The monitoring plan should address three time horizons: pre-treatment screening, per-dose self-monitoring, and ongoing follow-up.

Pre-Treatment Screening

Before initiating alprostadil in a patient already taking trazodone (or vice versa), clinicians should document:

• Baseline erectile function using a validated instrument such as the International Index of Erectile Function (IIEF-5) [9]
• History of prolonged erections or priapism episodes
• Sickle cell status, especially in patients of African, Mediterranean, or South Asian descent
• Concurrent use of other alpha-blockers, PDE5 inhibitors, or anticoagulants that could compound risk

Per-Dose Self-Monitoring Protocol

Patients should time every erection following alprostadil injection or MUSE insertion. The AUA recommends the following thresholds [8]:

• Erection 1 to 3 hours: acceptable if rigid; apply ice packs and walk if concerned
• Erection 3 to 4 hours: contact prescribing clinician; prepare for possible emergency department visit
• Erection exceeding 4 hours: proceed to the nearest emergency department for corporal aspiration and possible phenylephrine injection

This guidance applies regardless of trazodone co-administration, but patients on both drugs should be counseled to use the lower end of each time window as their action threshold.

Ongoing Follow-Up

Clinicians should reassess the combination at 4 to 6 week intervals during dose stabilization. If the patient's depressive symptoms are well-controlled, consider whether trazodone could be replaced with an antidepressant carrying lower alpha-1 antagonist activity (e.g., sertraline, which has minimal direct alpha-1 blockade) [10]. If trazodone is being used solely as a sleep aid, non-serotonergic alternatives such as melatonin receptor agonists (ramelteon) or low-dose doxepin may eliminate the pharmacodynamic overlap entirely.

Dose Adjustment Guidance

No formal pharmacokinetic dose adjustment is required because the interaction is not CYP-mediated. The clinical recommendation centers on conservative alprostadil titration.

Practical Titration Strategy

Start alprostadil at the lowest available dose (1.25 mcg for Caverject, 125 mcg for MUSE) when the patient is on stable trazodone therapy. Titrate upward by the smallest available increment, with a minimum 24-hour interval between doses and no more than three doses per week [3]. The in-office test dose should be administered while the patient is on their usual trazodone regimen, not during a trazodone washout, so the observed erectile response reflects real-world pharmacodynamic conditions.

Trazodone Timing Considerations

Trazodone's peak plasma concentration occurs approximately 1 to 2 hours after oral dosing, and its elimination half-life ranges from 5 to 9 hours [6]. Patients taking trazodone at bedtime for insomnia who use alprostadil the following evening (roughly 18 to 22 hours post-trazodone) will have substantially lower trazodone plasma levels than those who inject alprostadil within a few hours of their trazodone dose. Spacing the two drugs as far apart as the clinical scenario allows is a reasonable risk-reduction measure, though it does not eliminate the interaction.

Patient Counseling Points

Clear, specific counseling reduces the chance that a treatable prolonged erection becomes an ischemic emergency. The following points should be communicated verbally and reinforced in written take-home instructions.

What to Tell Every Patient

1. Both medications can independently cause prolonged erections. Using them together increases that risk.
2. Time every erection from onset. If rigidity persists beyond three hours, call the clinic. If it persists beyond four hours, go to the emergency department. Do not wait.
3. Do not use PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) concurrently unless specifically directed by the prescribing physician, as triple-stacking further escalates priapism risk [8].
4. Alcohol potentiates both the sedation of trazodone and the hypotensive effect of alprostadil. Limit alcohol to no more than one standard drink on days when both drugs are used.

Priapism Emergency Card

Provide patients with a wallet card listing their medications, the diagnosis of erectile dysfunction requiring intracavernosal therapy, and the instruction that corporal aspiration with or without intracavernosal phenylephrine is the standard emergency treatment. Emergency physicians unfamiliar with intracavernosal alprostadil may delay appropriate management without this context.

When to Reconsider the Combination

If a patient experiences even one episode of prolonged erection (defined as >2 hours of full rigidity) while on both medications, the risk-benefit calculation shifts. Options include reducing the alprostadil dose, switching the antidepressant or sleep aid, or discontinuing one of the two agents. A single episode of ischemic priapism treated with aspiration is associated with a 50% recurrence rate in susceptible individuals [11].

Special Populations

Older Adults

Men over 65 may have slower trazodone clearance due to age-related declines in hepatic CYP3A4 activity, extending the window of pharmacodynamic overlap [6]. The trazodone starting dose in older adults is typically 25 to 50 mg at bedtime (compared to 150 mg/day for depression in younger adults), which partially offsets this concern. Alprostadil titration should begin at the lowest increment regardless of age.

Sickle Cell Disease

The AUA and the FDA label for Caverject both list sickle cell disease as a relative contraindication to intracavernosal alprostadil due to the elevated baseline priapism risk [3][8]. Adding trazodone to this population creates a three-factor risk stack (sickling tendency, prostaglandin-mediated vasodilation, alpha-1 blockade). The combination should be avoided in these patients unless no alternative erectile dysfunction therapy is viable and the hematologist concurs.

Patients on Anticoagulation

Warfarin, apixaban, rivaroxaban, and other anticoagulants do not directly increase priapism risk, but they complicate emergency management. Corporal aspiration and phenylephrine irrigation are standard priapism treatments, and anticoagulated patients may experience prolonged bleeding at the aspiration site. Document anticoagulation status clearly in the medical record and on the patient's priapism emergency card.

The Bottom Line on Co-Prescribing

A 2018 retrospective cohort analysis of FDA Adverse Event Reporting System (FAERS) data found that trazodone ranked among the top five non-erectile-dysfunction drugs associated with priapism reports, alongside antipsychotics and other alpha-1 antagonists [12]. Alprostadil's own 4% prolonged-erection rate in clinical trials [3] means combining the two drugs places the patient at an additive (though not precisely quantified) elevation of a rare but serious event.

The combination is not contraindicated across the board. For men with refractory erectile dysfunction who also require trazodone for depression or insomnia, the pairing can be managed safely with proper titration, timing separation, patient education, and a low threshold for emergency evaluation. Prescribers should document the informed-consent discussion, including the specific risk of priapism, in the medical record at the time the combination is initiated.

The most protective single intervention is ensuring the patient can recite, unprompted, the four-hour rule: any erection lasting four hours or longer requires emergency department evaluation, no exceptions.